The actual benefit of ABRAXANE in combination with gemcitabine is substantial in the extension of indication “first-line treatment of adult patients with metastatic adenocarcinoma of the pancreas”
Clinical Added Value
minor
ABRAXANE in combination with gemcitabine provides a minor improvement in actual benefit (level IV) compared with gemcitabine monotherapy in the treatment of metastatic adenocarcinoma of the pancreas, in adult patients, as first-line treatment.
Listen
